GAVI signs Covid-19 vaccine supply deal with J&J
GAVI said the goal was to have the doses available in 2021 and for both self-financing participants of COVAX as well as poorer countries
Vials of Johnson & Johnson's Janssen coronavirus disease (COVID-19) vaccine candidate are seen in an undated photograph. Johnson & Johnson/Handout via REUTERS.
The GAVI Vaccine Alliance has signed an advanced purchase agreement with Johnson & Johnson for 200 million doses of its Covid-19 vaccine for the COVAX vaccine-sharing programme, it said in a statement on Friday.
GAVI said the goal was to have the doses available in 2021 and for both self-financing participants of COVAX as well as poorer countries.
"As a one dose vaccine, the J&J vaccine has particular relevance for places with difficult infrastructure, making it a very important addition to the portfolio," said GAVI CEO Seth Berkley.
Keep updated, follow The Business Standard's Google news channel
